Last reviewed · How we verify
MB-IMP
At a glance
| Generic name | MB-IMP |
|---|---|
| Also known as | MCT oil |
| Sponsor | Southwest Autism Research & Resource Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) (PHASE1)
- Venous Congestion And Delirium After Cardiac Surgery
- Venous Congestion and Cardiac Surgery-Associated Acute Kidney Injury
- Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (PHASE1)
- Intraoperatively Observed Site of Origin and Growth Pattern of Medulloblastoma
- Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults (PHASE2)
- Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-IMP CI brief — competitive landscape report
- MB-IMP updates RSS · CI watch RSS
- Southwest Autism Research & Resource Center portfolio CI